The effects of milnacipran on sleep disturbance in fibromyalgia: A randomized, double-blind, placebo-controlled, two-way crossover study

Journal of Clinical Sleep Medicine

Volumn 12, Issue 1, 2016, Pages 79-86

  Ahmed, Mansoor ^a   Aamir, Rozina ^a   Jishi, Zahra ^a   Scharf, Martin B ^a  

^a Cleveland Sleep Research Center   (United States)

Author keywords

Fibromyalgia; Milnacipran; Pain; Polysomnography; Sleep quality

Indexed keywords

ACETYLSALICYLIC ACID; ESCITALOPRAM; MILNACIPRAN; PARACETAMOL; PLACEBO; CYCLOPROPANE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BRIEF PAIN INVENTORY; CLINICAL ARTICLE; COLD SWEAT; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG ERUPTION; DRUG HALF LIFE; DRUG WITHDRAWAL; EJACULATION DISORDER; ELEVATED BLOOD PRESSURE; EVENING DOSAGE; FATIGUE SEVERITY SCALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; GALLSTONE; HEADACHE; HEART RATE; HOT FLUSH; HUMAN; INFLUENZA; MAINTENANCE THERAPY; MENSTRUATION; MICTURITION DISORDER; MORNING DOSAGE; NAUSEA AND VOMITING; NUMBER OF AWAKENINGS AFTER SLEEP ONSET; PERIODONTAL DISEASE; POLYSOMNOGRAPHY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINUSITIS; SLEEP DISORDER; SLEEP EFFICIENCY; SLEEP PARAMETERS; SORE THROAT; SPRAIN; SWEATING; TREATMENT DURATION; WAKE AFTER SLEEP ONSET; XEROSTOMIA; AGED; COMPLICATION; DOSE RESPONSE; FEMALE; MALE; MIDDLE AGED; PATIENT SATISFACTION; SEVERITY OF ILLNESS INDEX; SLEEP WAKE DISORDERS; TREATMENT OUTCOME;

ADULT; AGED; CROSS-OVER STUDIES; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; POLYSOMNOGRAPHY; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SLEEP WAKE DISORDERS; TREATMENT OUTCOME;

EID: 84956707806     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.5400     Document Type: Article

References (39)

1. Wolfe F, Ross K, Anderson J, Russel IJ, Hebert L. The prevalence and characteristics of fbromyalgia in the general population. Arthritis Rheum. 1995;38:19-28.
2. Affeck G, Urrows S, Tennen H, Higgins P, Abeles M. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fbromyalgia. Pain 1996;68;363-8.
3. Landis CA, Frey CA, Lentz MJ, Rethernel J, Buchwald D, Shaver JLF. Self reported sleep quality and fatigue correlates with actigraphy sleep indicators in midlife women with fbromyalgia. Nurs Res 2003;52:140-7.
4. Moldofsky H, Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med 1976;38:35-44.
5. Lentz MJ, Landis CA, Rothermel J, Shaver JL. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatol 1999;26:1586-92.
6. Roehrs T, Hyde M, Blaisdell B, Greenwald M, Roth T. Sleep loss and REM sleep loss are hyperalgesic. Sleep 2006;29:145-51.
7. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non-REM sleep disturbance in subjects with 'fbrositis syndrome' and healthy controls. Psychosom Med 1975;37:341-51.
8. Arnold LM, Crofford LJ, Mease PJ, et al. Subject perspectives on the impact of fbromyalgia. Subject Educ Couns 2008;73:114-20.
9. Yunus MB, Kaylan-Roman UP. Muscle biopsy fndings and primary fbromyalgia and other forms of non articular rheumatism. Rheum Dis Clin North Am 1989;15, 115-34.
10. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fbromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-10.
11. Burns JW, Crofford LJ, Chervin RD. Sleep stage dynamics in fbromyalgia subjects and controls. Sleep Med 2008;9:689-96.
12. Harding SM. Sleep in fbromyalgia subjects: subjective and objective fndings. Am J Med Sci 1998;315:367-76.
13. Jacobsen S. Chronic widespread musculoskeletal pain-the fbromyalgia syndrome.[Thesis] Dan Med Bull 1994;41:541-64.
14. Chervin R et al. Objective measures of disordered sleep in fbromyalgia. J Rheumatology 2009;36:9:2009-16.
15. Clauw DJ, Mease P, Palmer RH, Gendreau M, Wang Y. Milnaciprin for the treatment of fbromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multi-dose clinical trial. Clin Ther 2008;30:1988-2004.
16. Mease PJ, Clauw DJ, Gendreau RM, et al. The effcacy and safety of milnacipran for treatment of fbromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 36, 398-409, 2009.
17. Gendreau RM, Thorn MD, Gendreau J F, et al. Effcacy of milnacipran in subjects with fbromyalgia. J Rheumatol 2005;32:1975-85.
18. Goldenberg D, Clauw DJ, Palmer R, Mease P, Gendreau RM. One-year durability of response to milnacipran treatment for fbromyalgia. Arthritis Rheum 2007;56:S603.
19. Geisser ME, Clauw DJ, Strand V, Gendreau RM, Palmer R, Williams DA. Contributions of change in clinical status parameters to Subject Global Impression of Change (PGIC) scores among persons with fbromyalgia treated with milnacipran. Pain 2010;149:373-8.
20. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques, and scoring system for sleep stages of human subjects. NIH Publication. No 204. Washington, DC: US Government Printing Offce, 1968.
21. Iber C, Ancoli-Israel S, Chesson AL Jr, Quan SF. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifcations. Westchester, IL: American Academy of Sleep Medicine, 2007.
22. Spritzer KL, Hays RD. MOS Sleep Scale: a manual for use and scoring, Version 1.0. Los Angeles, CA, 2003.
23. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728-34.
24. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38.
25. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res 1993;37:753-62.
26. Beck AT, Steer RA, Brown GK. Beck Depression Inventory-Second Edition manual. San Antonio, TX, The Psychological Corporation, 1996:1-38.
27. Hurst H, Bolton J. Assessing the clinical signifcance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther 2004;27:26-35.
28. Traynor LM, Thiessen CN, Traynor AP. Pharmacotherapy of fbromyalgia. Am J Health Syst Pharm 2011:68:1307-19.
29. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fbromyalgia. Hum Psychopharmacol 2004;19:27-35.
30. Lemoine P, Faivre T. Subjective and polysomnographic effects of milnacipran on sleep in depressed subjects. Hum Psychopharmacol Clin Exp 2004;19:299-303.
31. Van Den Berg JF, Van Rooij FJ, Vos H, et al. Disagreement between subjective and actigraphic measures of sleep duration in a population-based study of elderly persons. J Sleep Res 2008;17:295-302.
32. Kay DB, Buysse DJ, Germain A, Hall M, Monk TH. Subjective-objective sleep discrepancy among older adults: associations with insomnia diagnosis and insomnia treatment. J Sleep Res 2015;24:32-9.
33. Hindmarch L, Rigney U, Stanley N, Briley M. Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharamacol 2000;49:118-25.
34. Vaikshnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affnity. Biol Psychiatry 2004;55:320-2.
35. Rahmadi M, Narita M, Yamashita A, Imai S, Kuzumaki N, Suzuki T. Sleep disturbance associated with an enhanced orexinergic system induced by chronic treatment with paroxetine and milacipran. Synapse 2011;7:652-7.
36. Agnew HW, Wess WB, Williams RL. The frst night effects: an EEG study of sleep. Psychophysiology 1996;4:2263-6.
37. Scharf MB, Bixler EO, Kales A. Readaptation to the sleep laboratory in insomnia subjects. Psychophysiology 1975;12:69-73.
38. Branco JC, Cherin P, Montagne A, Bouroubi A; Multinational Coordinator Study Group. Long term therapeutic response to milnacipran treatment for fbromyalgia. A European 1-year extension study following a 3-month study. J Rheumatol 2011:38:1403-12.
39. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fbromyalgia. Hum Psychopharmacol 2004;19:27-35.